Bioimaging in Radiotherapy for Lung Cancer

Investigators: Noah C. Choi, M.D. (PI) Alan Fischman, M.D.,Ph.D. Andrzej Niemierko, Ph.D Marek Ancukiewicz,Ph.D. Thomas Lynch, M.D. Douglas Mathisen,M.D. Richard Kradin, M.D.

Massachusetts General Hospital Harvard Medical School

Support: 1 RO1 EB02907-01

FDG Uptake Curve in Lung Cancer



Dose-Response Relationship Between pTCP And MRgIc



Follow-up Study 1

Primary Objective

To determine MRG, obtained 10-12 days after RT or RT of CT+R, which corresponds to cTCP \ge 95% at 12 months

Methods In vivo assay in a clinical setting (Partners Protocol 03-282)

STUDY SCHEMA (Protocol 03-282)



18F-FDG PET: 18F-fluoro-2-deoxy-D-glucose (18F-FDG) and positron emission tomography (PET), CRT: Concurrent chemoradiotherapy, RT: Radiation therapy, 18F-FLT PET: 3'-deoxy-3'-[18-F] fluorothymidine (18F-FLT) PET.

Timetable for Overall Project (Protocol 03-282)

Study Period (Year)	1	2	3	4	5	Total
Patients to be accrued per year	40	41	41	-	-	122
Patients eligible for 18F-FDG PET 10-12 days after RT of CRT or RT*	35	35	35	-	-	105
Number of patients eligible for 18F-FDG PET at 3 months**	18	28	28	10	-	84
Number of patients eligible for 18F-FDG PET at 6 months***	12	24	24	12	-	72
Number of patients eligible for 18F-FDG PET at 12 months****	0	16	16	16	-	48
Number of patients eligible for 18F-FLT PET##	10	16	16	6	-	48

Progress Report

- Study Protocol: Partners 03-282
 Date of Activation 12/29/03
 Patient Accrual 16 patients in 4.5 months
 Number of patients to be accrued 40 (first year)
- 2. Number of FDG PET studies7 patients 2 studies9 patients 1 study

Bio-image Guided Target for Radiation

CT Image

Fused CT-PET Image



Poorly Defined Tumor Margins

FDG Avid Tumor